Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study
To estimate the antitumor activity of 9-aminocamptothecin (9-AC) in patients with recurrent platinum-aaaresistantaaa ovarian cancer; and to determine the nature and degree of toxicity of 9-AC in this cohort of patients.